Bristol-Myers Squibb accused of misusing market power with cancer treatment program

Bristol-Myers Squibb 2021-07-19 2:55 pm By Miklos Bolza | Sydney

Please login to bookmark

Merck Sharp & Dohme has filed a lawsuit accusing rival drug company Bristol-Myers Squibb of misusing its market power by restricting access to a treatment program for stage IV melanoma patients.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au